X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (16620) 16620
Book Review (4492) 4492
Publication (1525) 1525
Newsletter (446) 446
Newspaper Article (257) 257
Book Chapter (106) 106
Transcript (45) 45
Conference Proceeding (40) 40
Magazine Article (31) 31
Dissertation (21) 21
Book / eBook (9) 9
Data Set (3) 3
Web Resource (3) 3
Trade Publication Article (2) 2
Paper (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (13898) 13898
humans (12309) 12309
angiogenesis (8588) 8588
female (6331) 6331
male (5891) 5891
oncology (5258) 5258
animals (4780) 4780
cancer (4575) 4575
middle aged (4151) 4151
bevacizumab (4065) 4065
angiogenesis inhibitors - therapeutic use (3985) 3985
aged (3808) 3808
vascular endothelial growth factor (3438) 3438
endothelial growth-factor (3321) 3321
angiogenesis inhibitors (3305) 3305
angiogenesis inhibitors - adverse effects (2878) 2878
care and treatment (2811) 2811
adult (2807) 2807
treatment outcome (2696) 2696
chemotherapy (2340) 2340
research (2297) 2297
angiogenesis inhibitors - administration & dosage (2223) 2223
mice (2145) 2145
ophthalmology (2134) 2134
metastasis (2095) 2095
vascular endothelial growth factor a - antagonists & inhibitors (2035) 2035
pharmacology & pharmacy (1891) 1891
analysis (1873) 1873
tumors (1809) 1809
expression (1757) 1757
therapy (1722) 1722
aged, 80 and over (1697) 1697
health aspects (1631) 1631
apoptosis (1559) 1559
medicine & public health (1541) 1541
antineoplastic agents - therapeutic use (1452) 1452
antibodies, monoclonal, humanized (1412) 1412
drug therapy (1387) 1387
vegf (1359) 1359
clinical trials (1292) 1292
antineoplastic combined chemotherapy protocols - therapeutic use (1252) 1252
macular degeneration (1222) 1222
neovascularization (1219) 1219
proteins (1180) 1180
cancer therapies (1135) 1135
intravitreal injections (1130) 1130
neoplasms - drug therapy (1130) 1130
ranibizumab (1118) 1118
surgery (1111) 1111
angiogenesis inhibitors - pharmacology (1098) 1098
studies (1090) 1090
retrospective studies (1073) 1073
medicine (1051) 1051
risk factors (1028) 1028
neovascularization, pathologic - drug therapy (1016) 1016
physiological aspects (1013) 1013
cell biology (1012) 1012
cells (986) 986
inflammation (966) 966
development and progression (957) 957
article (953) 953
kinases (948) 948
antibodies, monoclonal - therapeutic use (946) 946
rats (944) 944
research article (928) 928
gene expression (918) 918
medical research (917) 917
cell line, tumor (912) 912
survival (907) 907
abridged index medicus (904) 904
medicine, research & experimental (903) 903
disease-free survival (898) 898
rodents (887) 887
prognosis (881) 881
vascular endothelial growth factor a - metabolism (874) 874
patients (870) 870
follow-up studies (861) 861
antineoplastic agents (860) 860
antibodies, monoclonal - adverse effects (852) 852
hematology (842) 842
antineoplastic agents - adverse effects (839) 839
breast cancer (838) 838
tumor angiogenesis (836) 836
hematology, oncology and palliative medicine (835) 835
signal transduction (829) 829
in-vivo (826) 826
antimitotic agents (820) 820
hypertension (798) 798
endothelium (791) 791
prospective studies (784) 784
growth (783) 783
antibodies, monoclonal, humanized - therapeutic use (782) 782
dose-response relationship, drug (782) 782
time factors (777) 777
trial (766) 766
disease models, animal (762) 762
in-vitro (758) 758
inhibition (752) 752
review (752) 752
colorectal cancer (748) 748
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (17127) 17127
French (106) 106
German (89) 89
Japanese (54) 54
Spanish (38) 38
Chinese (22) 22
Russian (11) 11
Hungarian (8) 8
Polish (8) 8
Italian (6) 6
Czech (4) 4
Dutch (4) 4
Danish (3) 3
Swedish (3) 3
Korean (2) 2
Finnish (1) 1
Hebrew (1) 1
Norwegian (1) 1
Romanian (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, pp. CD007419 - CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor... 
CLINICAL-TRIAL | RANIBIZUMAB PLUS PROMPT | RANDOMIZED CONTROLLED-TRIAL | Receptors, Vascular Endothelial Growth Factor [therapeutic use] | DEFERRED LASER | MEDICINE, GENERAL & INTERNAL | PEGAPTANIB SODIUM | Bevacizumab [adverse effects; therapeutic use] | Laser Coagulation [methods] | Aptamers, Nucleotide [adverse effects; therapeutic use] | Network Meta-Analysis | QUALITY-OF-LIFE | Macular Edema [drug therapy; etiology; surgery] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Visual Acuity [drug effects; physiology] | COST-EFFECTIVENESS | Angiogenesis Inhibitors [adverse effects; therapeutic use] | LASER PHOTOCOAGULATION | Randomized Controlled Trials as Topic | Ranibizumab [adverse effects; therapeutic use] | Recombinant Fusion Proteins [adverse effects; therapeutic use] | Quality of Life | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | Triamcinolone [adverse effects; therapeutic use] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9807, pp. 1931 - 1939
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2015, Volume 33, Issue 2, pp. 172 - 179
Purpose This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma... 
ANGIOGENESIS | ONCOLOGY | PATHWAY | SUNITINIB | ABT-869 | RISK | BRIVANIB | INHIBITOR | CANCER | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Hand-Foot Syndrome - etiology | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Liver Neoplasms - etiology | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Hypertension - chemically induced | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Liver Neoplasms - pathology | Carcinoma, Hepatocellular - etiology | Odds Ratio | Drug Administration Schedule | Risk Factors | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Niacinamide - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Sorafenib | Carcinoma, Hepatocellular - pathology | Aged | Indazoles - adverse effects | Indazoles - therapeutic use | Index Medicus | Bone3 | ORIGINAL REPORTS | Bios3
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 8, pp. 760 - 767
Purpose This international phase III trial (Investigating Torisel As Second-Line Therapy [INTORSECT]) compared the efficacy of temsirolimus (mammalian target... 
SURVIVAL | INTERFERON-ALPHA | EVEROLIMUS | ONCOLOGY | BEVACIZUMAB | DOUBLE-BLIND | AGENTS | Niacinamide - analogs & derivatives | TOR Serine-Threonine Kinases - metabolism | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | TOR Serine-Threonine Kinases - antagonists & inhibitors | Young Adult | Receptors, Vascular Endothelial Growth Factor - metabolism | Time Factors | Phenylurea Compounds - adverse effects | Treatment Failure | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Carcinoma, Renal Cell - enzymology | Female | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Kaplan-Meier Estimate | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Kidney Neoplasms - mortality | Disease Progression | Carcinoma, Renal Cell - mortality | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Kidney Neoplasms - enzymology | Indoles - therapeutic use | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Index Medicus | ORIGINAL REPORTS
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2007, Volume 356, Issue 2, pp. 115 - 124
Sunitinib is one of several new antiangiogenic agents undergoing tests of efficacy in the treatment of various types of cancer. Renal-cell carcinoma of the... 
PHASE-III TRIAL | MEDICINE, GENERAL & INTERNAL | FUNCTIONAL ASSESSMENT | DOSE RECOMBINANT INTERLEUKIN-2 | CLINICAL-TRIALS | IN-VIVO | TUMOR-SUPPRESSOR GENE | TYROSINE KINASE INHIBITOR | RANDOMIZED-TRIAL | FACTOR RECEPTOR | ENDOTHELIAL GROWTH-FACTOR | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Pyrroles - adverse effects | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Female | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Receptors, Platelet-Derived Growth Factor - antagonists & inhibitors | Risk Factors | Interferon-alpha - therapeutic use | Kaplan-Meier Estimate | Kidney Neoplasms - mortality | Disease Progression | Carcinoma, Renal Cell - mortality | Indoles - adverse effects | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Quality of Life | Indoles - therapeutic use | Kidney Neoplasms - pathology | Aged | Interferon-alpha - adverse effects | Kidney Neoplasms - drug therapy | Carcinoma, Renal cell | Comparative analysis | Drug therapy | Interferon alpha | Clinical trials | Interferon | Cytokines | Vascular endothelial growth factor | Skin cancer | Index Medicus | Abridged Index Medicus
Journal Article
JAMA, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | FIRE-3 | THERAPY | FOLFIRI PLUS CETUXIMAB | PHASE-II | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | TUMORS | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Randomization | Oxaliplatin | Monoclonal antibodies | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 8, pp. 722 - 731
Journal Article